“…Propranolol, the first clinically useful b-adrenergic receptor 14 antagonist, was introduced to the clinical practice in the treatment 15 of cardiovascular diseases [1,2], angina pectoris [3,4], infantile 16 haemangiomas [5,6], many neuropsychiatric disorders [7], dental 17 anxiety [8] and pulmonary hemangioma [9]. In addition, propran-18 olol suppressed neuronal voltage-gated sodium currents [10,11], 19 and therefore produced a local (termed topical) anesthetic effect 20 [2,3,12], including sciatic nerve block [12], spinal anesthesia 21 [13,14] and infiltrative cutaneous analgesia [15,16].…”